SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCQB: GNSZ) (“GenSpera” or the “Company”), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, today announced that it has entered into definitive agreements with institutional investors, led by a healthcare-dedicated fund, for the private placement of shares of convertible preferred stock and warrants to purchase shares of common stock and the exercise of certain outstanding warrants for gross proceeds of approximately $2.5 million.
